Soluble Guanylate Cyclase Stimulator [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the soluble guanylate cyclase stimulator [epc] class. 38 active patents protecting 2 drugs. First major cliff: 2026. Daily refresh.

2
Drugs in class
38
Active US patents
54/100
Avg vulnerability
—
Annual revenue covered

Originators

Bayer 20 patents Merck & Co. 18 patents

Cliff calendar — next 15 years

5
26
15
31
3
32
15
34

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Adempas
RIOCIGUAT
 Bayer 20 59 — 2026-12-04
Verquvo
VERICIGUAT
 Merck & Co. 18 49 — 2031-05-19

Most attackable patents

Patent Drug Type Vuln Expiry
11439642 Verquvo method of use 76 2031-05-19
11439642 Verquvo method of use 76 2031-05-19
11439642 Verquvo method of use 76 2031-05-19
12503469 Adempas method of use 75 2034-02-18
12503469 Adempas method of use 75 2034-02-18
12503469 Adempas method of use 75 2034-02-18
12503469 Adempas method of use 75 2034-02-18
12503469 Adempas method of use 75 2034-02-18
11203593 Adempas method of use 70 2034-02-18
11203593 Adempas method of use 70 2034-02-18

Strongest defences

Patent Drug Type Vuln Expiry
10736896 Verquvo composition of matter 10 2031-05-19
10736896 Verquvo composition of matter 10 2031-05-19
8420656 Verquvo composition of matter 10 2031-05-19
8420656 Verquvo composition of matter 10 2031-05-19
8420656 Verquvo composition of matter 10 2031-05-19
10736896 Verquvo composition of matter 10 2031-05-19
7173037 Adempas composition of matter 27 2026-12-04
7173037 Adempas composition of matter 27 2026-12-04
7173037 Adempas composition of matter 27 2026-12-04
7173037 Adempas composition of matter 27 2026-12-04

Related